Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation

Core Viewpoint - Sanofi has reached an agreement with the US government to lower medicine costs while promoting innovation in biopharmaceutical manufacturing [1][2][8] Group 1: Agreement Details - The agreement is voluntary and confidential, addressing all four requests from President Trump's letter dated July 31, 2025 [2] - It establishes a sustainable framework for US leadership in scientific research and development [2] - State Medicaid programs will access certain Sanofi medicines at prices equivalent to those in other high-income nations, resulting in an average price reduction of 61% for specific medicines treating diabetes, cardiovascular, neurological conditions, and cancer [3] Group 2: Consumer Access and Pricing - Consumers will have access to lower-cost medicines through TrumpRx.gov and other direct-to-patient platforms, with average savings of nearly 70% on certain medicines for infections and cardiovascular and diabetic conditions [3] - Sanofi will align the Medicaid price of several marketed medicines with those in other high-income countries [9] Group 3: Commitment to Innovation and Manufacturing - The agreement includes a three-year exemption from Section 232 tariffs on products imported by Sanofi, without impacting the company's growth strategy or financial outlook during this period [5] - Sanofi plans to invest $20 billion in upgrading manufacturing facilities, building new supply capacity, and expanding manufacturing partnerships [9] - The company operates over 15 sites in the US, employing more than 13,000 people, including over 2,200 research scientists [6]